1Guy's and St Thomas' NHS Foundation Trust, London, 2Russells Hall Hospital, Dudley,
West Midlands, 3Arrowe Park Hospital Arrowe Park Road Upton Wirral, 4Wellcome Trust …

Background We conducted a randomized comparison of hydroxyurea with anagrelide in the
treatment of essential thrombocythemia. Methods A total of 809 patients with essential …

Summary Background An acquired V617F mutation in JAK2 occurs in most patients with
polycythaemia vera, but is seen in only half those with essential thrombocythaemia and …

Activating mutations of MPL exon 10 have been described in a minority of patients with
idiopathic myelofibrosis (IMF) or essential thrombocythemia (ET), but their prevalence and …

Acute myeloid leukemia (AML) may follow a JAK2-positive myeloproliferative neoplasm
(MPN), although the mechanisms of disease evolution, often involving loss of mutant JAK2 …

The role of histopathology in the diagnosis of essential thrombocythemia (ET) is
controversial, and there has been little attempt to quantitate interobserver variability …

Background Previous studies have demonstrated increased markers of thrombogenesis in
patients with atrial fibrillation (AF), suggesting the presence of a hypercoagulable or …

Background and Purpose—We hypothesized that different ethnic groups would have
different levels of knowledge and perceptions of atrial fibrillation (AF) and of their …

Purpose Essential thrombocythemia (ET) manifests substantial interpatient heterogeneity in
rates of thrombosis, hemorrhage, and disease transformation. Bone marrow histology …

Approximately 50% of essential thrombocythaemia and primary myelo‐fibrosis patients do
not have a JAK2 V617F mutation. Up to 5% of these are reported to have a MPL exon 10 …